Walking aids with training and falls in people with muscle and nerve diseases
Tests walking aids plus physiotherapy on fall risk in people with neuromuscular diseases.
Plain-language title generated from the registry record
Registry title: The Use of Assistive Gait Devices Can Reduce the Risk of Falls in Patients With Neuromuscular Diseases Following a Training Period.
Key facts
- Where
- Bad Feilnbach, GermanySee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 65 with a confirmed neuromuscular disease who can think and communicate well enough. It tests a walking aid with training to see if it lowers the risk of falls.
- Age
- 65 years (both the minimum and maximum age in the record are 65 years)
- Sex
- All sexes can join.
- Disease stage
- A neuromuscular disease confirmed by a genetic report and/or a final clinical diagnosis. Conditions listed include inclusion body myositis, myotonic dystrophy, Pompe disease, myasthenia gravis, spinal muscular atrophy and Guillain-Barré syndrome.
- Earlier treatment
- Not stated. People who had knee, hip or back surgery in the last three months cannot join.
- Biomarker or test result
- A genetic report can confirm the diagnosis. No specific gene or marker is named.
Main reasons for not taking part
- Score of more than 23 points on the Falls Efficacy Scale-International
- Cannot walk at least ten metres without help
- Knee, hip or back surgery in the last three months
- Polyneuropathy without a diagnosis of inflammatory autoimmune neuropathy
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 65 and 65 years old?
Source: NCT07072676, who can take part
Where in Germany
- Medical Park, Bad Feilnbach, ReithofparkBad Feilnbach, GermanyNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- LMU Klinikum
- Trial code
- NCT07072676
- Record updated
- 18 July 2025
- Original description
The planned project is an intervention study to assess the risk of falling after adaptation of an assistive gait devices in patients with the following neuromuscular diseases: Inclusion body myositis, myotonic dystrophy, limb girdle and facioscapulohumeral muscular dystrophies, Pompe disease, Lambert-Eaton syndrome, myasthenia gravis, spinal muscular atrophy, Guillain-Barré syndrome, chronic inflammatory demyelinating polyradiculoneuropathy, Friedreich's ataxia and hereditary motor and sensory neuropathy.Read full original descriptionShow less
The Use of Assistive Gait Devices Can Reduce the Risk of Falls in Patients With Neuromuscular Diseases Following a Training Period.
The planned project is an intervention study to assess the risk of falling after adaptation of an assistive gait devices in patients with the following neuromuscular diseases: Inclusion body myositis, myotonic dystrophy, limb girdle and facioscapulohumeral muscular dystrophies, Pompe disease, Lambert-Eaton syndrome, myasthenia gravis, spinal muscular atrophy, Guillain-Barré syndrome, chronic inflammatory demyelinating polyradiculoneuropathy, Friedreich's ataxia and hereditary motor and sensory neuropathy.
The primary aim is to assess the risk of falling after a suitable assistive gait device has been provided with an adaptation phase through training. The data should help to improve the provision of aids for patients with neuromuscular diseases. This should have a positive effect on the risk of falling and thus improve quality of life and reduce mortality and morbidity. To achieve these goals, a one-week intervention with training sessions on handling, balance and coordination as well as fall prevention will becarried out after the patient has been fitted with a suitable assistive gait device.
The interventions will be embedded in the inpatient rehabilitation programme. The functional gait and balance tests 'Timed Up and Go', '10 metre walk test', '6-minute walk test' and 'Dynamic Gait Index' will be recorded additionally.
The Falls Efficacy Scale International questionnaire will be utilised to evaluate the risk of falling, while the Quebec User Evaluation of Satisfaction with Assistive Technology questionnaire will be employed to ascertain satisfaction with the assistive devices. The study is scheduled to run for a period of 14 days, during which participants will undergo three functional walking and balance tests. As part of the inpatient rehabilitation programme, participants will undergo a week-long period of rehabilitation without assistive technology, followed by a subsequent week of rehabilitation with adapted assistive technology.
Inclusion: The Patients with sufficient cognitive and communicative abilities,; The Patients with confirmed by the genetic report and/or the final clinical diagnosis.
Exclusion: The patient had knee, hip or back surgery in the last three months; Patients suffering from polyneuropathy without a diagnosis of inflammatory autoimmune neuropathy; The Patients scored more than 23 points on the falls efficacy Scale-International; The Patients are unable to walk at least ten metres without assistance,.